Name: UMIN ID:
Unique ID issued by UMIN | UMIN000011552 |
---|---|
Receipt number | R000013517 |
Scientific Title | Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancer |
Date of disclosure of the study information | 2013/08/22 |
Last modified on | 2016/11/16 09:05:53 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/08/22 17:10:37 | ||
2 | Update | 2016/06/28 12:36:45 | UMIN ID1 |
|
3 | Update | 2016/11/16 09:04:41 | Control Key inclusion criteria |
|
4 | Update | 2016/11/16 09:05:31 | Email Name of person sending information Name of person sending information Name of primary person or sponsor Organization |
|
5 | Update | 2016/11/16 09:05:53 | Recruitment status |